Scout | Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33

This opportunity is no longer accepting applications.

grant

Catalyze: Product Definition for Small Molecules and Biologics - Preliminary Product/Lead Series Identification (R33 - Clinical Trial Not Allowed)

This grant offers early-stage funding to help researchers identify lead compounds for developing treatments for heart, lung, blood, and sleep diseases. It is part of a Catalyze initiative designed to advance projects so they can qualify for further development programs or attract additional support from federal or private partners for preclinical work.

Source

Agency: National Institutes of Health

Sub-agency: National Heart, Lung, and Blood Institute

Award

Award Ceiling: $350,000

Funding Amount: $350,000

Dates

Opportunity Released: January 24, 2022

Open for Submission: January 24, 2022

Submission Deadline: December 20, 2024

Application Window Closes: December 20, 2024

Keywords

heart diseases

lung diseases

blood disorders

sleep disorders

therapeutic agents

translational support

lead compound series

preclinical development

NHLBI Catalyze

innovation grants

Supporting Links

Documents

Similar Opportunities

Unlock similar opportunities

Get the full picture on this opportunity

Create a free Scout account to unlock everything you need to decide fast and win the grant.

Instant Fit Analysis

Let our grant expert AI score how well this opportunity aligns with your organization, strengths, gaps, and how to improve your chances of winning funding.
Deep agency & funder detail

Program context, sub-agency structure, and a full eligibility breakdown.
Source links & full documents

Jump straight to the solicitation and download every attachment.
Similar opportunities

Discover related funding matched to your work.

Get a Demo Sign Up

Already have an account? Sign In

Trusted by 500+ Happy Customers